CIK 0000921299
- Non-accelerated filer
- Smaller reporting company
KYNTRA BIO, INC.
Sign in to watch- Ticker
- KYNB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 770357827
- Phone
- +1 415-978-1200
- Business address
- 350 BAY STREET, SUITE 100 #6009, SAN FRANCISCO, CA, 94133
- Former names
- FIBROGEN INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-05-26 | Cravatt Benjamin Director | Grant or award · Stock Option (Right to Buy) | +7,800 | 7,800 | ||
| 2021-05-26 | Brennan Aoife Director | Grant or award | +4,700 | 8,614 | ||
| 2021-05-26 | Brennan Aoife Director | Grant or award · Stock Option (Right to Buy) | +7,800 | 7,800 | ||
| 2021-05-26 | Blaug Suzanne Director | Grant or award | +4,700 | 14,048 | ||
| 2021-05-26 | Blaug Suzanne Director | Grant or award · Stock Option (Right to Buy) | +7,800 | 7,800 | ||
| 2021-03-11 | KEARNS THOMAS F JR Director | Option exercise | +18,000 | $3.50 | $63K | 166,164 |
| 2021-03-11 | KEARNS THOMAS F JR Director | Sale | −18,000 | $35.02 | $630K | 148,164 |
| 2021-03-11 | KEARNS THOMAS F JR Director | Option exercise · Stock Option (Right to Buy) | −12,000 | 0 | ||
| 2021-03-11 | KEARNS THOMAS F JR Director | Option exercise · Stock Option (Right to Buy) | −6,000 | 0 | ||
| 2021-03-08 | Kouchakji Elias SVP, Clinical Dev, Drug Safety | Shares withheld for taxes | −5,221 | $33.37 | $174K | 147,346 |
| 2021-03-08 | Cotroneo Pat SVP, Finance and CFO | Shares withheld for taxes | −5,657 | $33.37 | $189K | 282,187 |
| 2021-03-08 | Chung Christine SVP, China Operations | Shares withheld for taxes | −5,679 | $33.37 | $190K | 166,597 |
| 2021-02-24 | Wettig Thane Chief Commercial Officer | Grant or award | +16,500 | 47,150 | ||
| 2021-02-24 | Wettig Thane Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +32,100 | 32,100 | ||
| 2021-02-24 | Kouchakji Elias SVP, Clinical Dev, Drug Safety | Grant or award | +20,800 | 152,567 | ||
| 2021-02-24 | Kouchakji Elias SVP, Clinical Dev, Drug Safety | Grant or award · Stock Option (Right to Buy) | +39,900 | 39,900 | ||
| 2021-02-24 | Cotroneo Pat SVP, Finance and CFO | Grant or award | +21,700 | 287,844 | ||
| 2021-02-24 | Cotroneo Pat SVP, Finance and CFO | Grant or award · Stock Option (Right to Buy) | +41,700 | 41,700 | ||
| 2021-02-24 | Chung Christine SVP, China Operations | Grant or award | +21,700 | 172,276 | ||
| 2021-02-24 | Chung Christine SVP, China Operations | Grant or award · Stock Option (Right to Buy) | +41,700 | 41,700 |
Page 16 of 16 · 320 trades